DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
Despite significant advances in the treatment of acute myeloid leukemia (AML) Cream the long-term prognosis remains relatively poor and there is an urgent need for improved therapies with increased potency and tumor selectivity.Mylotarg is the first AML-targeting drug from a new generation of antibody drug conjugate (ADC) therapies aiming at the ac